discovery of glp 1 Glucagon-like peptide-1 Why GLP-1 drugs are changing

Discuss eligibility with your physician

Wegovy is still covered for heart-attack and stroke risk reduction (BMI 27 or higher with established cardiovascular disease, no diabetes) and for MASH, a fatty liver disease

Tuy nhin, v c qu nhiu loi vi cht lng khc nhau cha c kim chng nn vic tm mua c mt sn phm cht lng v an ton lun l ni lo lng ca rt nhiu ngi

For example, GLP-1RAs may modulate the CD36-JNK-AP1 pathway by partially down-regulating prolyl 4-hydroxylase subunit alpha-1 (P4HA1), and then inhibit ROS production mediated by Ang II type I receptor, thereby ameliorating cardiac fibroblast proliferation and myocardial fibrosis [167, 168]

GLP-1s are not appropriate for everyone, but for the right patients, they are a game changer